Novartis unveils more positive data for oral MS drug Gilenia

Novartis is touting more positive data for Gilenia (FTY720), the company's late-stage oral multiple sclerosis drug. The data, which were presented at the American Academy of Neurology meeting, demonstrated that Gilenia prevented relapse in 62 percent of treatment-naïve patients, while relapse rates were reduced by 44 percent in those who'd already received other treatments. In addition, at two years, Gilenia delayed the progression of disability by 30 percent for...